Ketamine

Hudson Health Announces Launch of Hudson Mind

Retrieved on: 
Tuesday, August 2, 2022

NEW YORK, Aug. 2, 2022 /PRNewswire/ --Hudson Health, formerly known as Hudson Medical Group , today announced the official launch of its newest development Hudson Mind.

Key Points: 
  • NEW YORK, Aug. 2, 2022 /PRNewswire/ --Hudson Health, formerly known as Hudson Medical Group , today announced the official launch of its newest development Hudson Mind.
  • Now, with the addition of Hudson Mind, Hudson Health delivers the ultimate mind and body care experience.
  • With the official launch of Hudson Mind, Hudson Health has built out a data-driven, multi-disciplinary approach to care that encompasses mind and body.
  • Established in 2010, Hudson Health has evolved from an Interventional Pain Management practice to a multidisciplinary collective spanning medical, wellness, and mental health care.

Limitless Guided Visualizations App Partners with International Regenerative Medicine Provider BioReset Medical®️ to Improve Patient Outcomes

Retrieved on: 
Tuesday, August 2, 2022

SAN JOSE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Limitless Guided Visualizations (Limitless) today announced its first partnership with BioReset Medical, an international network of regenerative medicine clinics, to provide a first-of-its-kind approach to ketamine therapy.

Key Points: 
  • SAN JOSE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Limitless Guided Visualizations (Limitless) today announced its first partnership with BioReset Medical, an international network of regenerative medicine clinics, to provide a first-of-its-kind approach to ketamine therapy.
  • The BioReset Medical Stress Reset treatment packages integrate advanced medical techniques (including ketamine and stellate ganglion blocks) with added cognitive support through the Limitless app.
  • We are thrilled to partner with BioReset Medical visionaries who provide world-class regenerative medicine to their patients.
  • Every BioReset patient who medically qualifies for the Stress Reset package receives a year of premium access to the Limitless Guided Visualizations mobile app to support their healing journey.

Irwin Naturals Emergence Making Immediate Impact in New England

Retrieved on: 
Thursday, July 28, 2022

Additionally, Irwin Naturals Emergence has reached binding agreements to acquire facilities in Georgia and in Vermont.

Key Points: 
  • Additionally, Irwin Naturals Emergence has reached binding agreements to acquire facilities in Georgia and in Vermont.
  • Casey Brachvogel, CRNA & founder of New England Ketamine, added that Becoming part of Irwin Naturals Emergence gives us a boost that comes from being part of a truly household brand name.
  • The goal of expanding access to life-changing care is a central component for Irwin Naturals Emergence.
  • Additionally, Irwin Naturals Emergence reached binding agreements to acquire two facilities in Georgia and one in Vermont .

HEMPLUCID BECOMES FIRST STARTUP TO PROVIDE PSYCHEDELIC THERAPY AS EMPLOYEE HEALTHCARE BENEFIT

Retrieved on: 
Thursday, July 28, 2022

PROVO, Utah, July 28, 2022 /PRNewswire/ -- HempLucid, a leading provider of plant-based wellness supplements, is the first startup to offer medically supervised Ketamine-Assisted Therapy (KAP) as an employee benefit.

Key Points: 
  • PROVO, Utah, July 28, 2022 /PRNewswire/ -- HempLucid, a leading provider of plant-based wellness supplements, is the first startup to offer medically supervised Ketamine-Assisted Therapy (KAP) as an employee benefit.
  • The employee benefit ensures access to KAP to any employee with a mental health diagnosis.
  • Traditional therapy is covered through HempLucid's existing health care plan and HempLucid continues to cover ketamine infusions.
  • The combination of traditional therapy and ketamine infusions is the medical therapy known as KAP.

Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

Retrieved on: 
Wednesday, July 27, 2022

ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study.

Key Points: 
  • Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system
    ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc .
  • (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study.
  • These results indicate that the dosing of Ketamine using a patent protected delivery system with Silo Pharmas partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in a small animal study.
  • Eric Weisblum, CEO of Silo Pharma, commented, These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction.

Braxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer and Global Pharmaceutical Industry Leader as VP R&D and Growth

Retrieved on: 
Wednesday, July 27, 2022

These strategic hires bolster Braxia's senior leadership team and its ability to drive growth and innovation.

Key Points: 
  • These strategic hires bolster Braxia's senior leadership team and its ability to drive growth and innovation.
  • Jason also brings deep expertise in both revenue cycle, data management and mining, and a proven ability to manage product development.
  • Jason is also a founding board member for a rare disease foundation working towards building treatments for children with Neurodegenerative disorders.
  • Dr. McIntyre commented, "We are delighted to welcome Daniel, adding high caliber global pharmaceutical leadership to the Braxia management team.

Ketamine Therapy Hyper-Local Content Marketing Service Launched by Alcyone

Retrieved on: 
Tuesday, July 26, 2022

Its omnipresent approach to content marketing allows it to build authority with both SERPs and potential customers.

Key Points: 
  • Its omnipresent approach to content marketing allows it to build authority with both SERPs and potential customers.
  • With the new content marketing service, Alcyone aims to establish ketamine clinics as trustworthy and authoritative options in their local area.
  • By running hyper-local marketing campaigns using targeted content strategies, the company strives to organically improve the client's Google ranking and Google 3-Pack position using white-hat marketing techniques.
  • With the launch of the new service, Alcyone affirms its commitment to helping ketamine therapy providers leverage content marketing to increase brand awareness and online visibility.

Delic 2021 Revenue Shows Strong Growth as Nation's Largest Ketamine Clinic Chain, Continues Expansion of Mental Health Wellness Services

Retrieved on: 
Thursday, July 21, 2022

Ketamine Wellness Centers (KWC) currently has 13 operational, state-of-the-art clinics that accept insurance and they are approaching 100,000 treatments to clinically eligible patients.

Key Points: 
  • Ketamine Wellness Centers (KWC) currently has 13 operational, state-of-the-art clinics that accept insurance and they are approaching 100,000 treatments to clinically eligible patients.
  • KWC launched the Ketamine Wellness Integrative Therapist Directory, connecting KWC patients with qualified mental health practitioners.
  • Delic announced its first annual earningsfor 2021 and reported revenue in excess of USD$1.5MM and increased net assets from USD$2.1MM in 2020 to USD$10MM.
  • Delic continues to focus on accelerating growth through the expansion of its national chain of Ketamine Wellness Centers (KWC) and the addition of numerous new programs and services.

Pasithea Therapeutics Awarded a Drug Development Research Grant

Retrieved on: 
Thursday, July 14, 2022

MIAMI BEACH, Fla., July 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the availability of an AUD $1 million (U.S. $694,000) drug development research award following the Company's acquisition of Alpha-5 integrin, LLC (“Alpha-5”). The grant was awarded by FightMND, the largest independent funder of amyotrophic lateral sclerosis (“ALS”)/motor neuron disease (“MND”) research in Australia.

Key Points: 
  • -- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction --
    MIAMI BEACH, Fla., July 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) Pasithea Therapeutics Corp. (Nasdaq: KTTA) (Pasithea or the Company), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the availability of an AUD $1 million (U.S. $694,000) drug development research award following the Company's acquisition of Alpha-5 integrin, LLC (Alpha-5).
  • The grant was awarded by FightMND, the largest independent funder of amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) research in Australia.
  • Ultimately, we aim to help ALS/MND patients who are in dire need of effective therapy, stated Dr. Tiago Reis Marques, CEO of Pasithea.
  • Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.

TMS Health and Wellness Welcomes Board-Certified Psychiatrist To Its Premier Clinical Care Team

Retrieved on: 
Wednesday, July 13, 2022

COSTA MESA, Calif., July 13, 2022 /PRNewswire-PRWeb/ -- TMS Health and Wellness (TMSHW) today announced the addition of Sylvia C. Guthrie, MSN, PMHNP-BC, to the experienced therapeutic healthcare staff at its clinic in Costa Mesa, California. Guthrie brings over seven years of experience to TMSHW, including a proven ability to oversee care for critically ill patients, deliver psychiatric mental health assessments, and diagnose and treat illness. Before joining TMSHW, Guthrie spent much of her career as a charge nurse at Aurora Las Encinas Mental Health Hospital in Pasadena, CA, where she managed staff and precepted nursing students and clinical duties. She holds a board certification as a critical care registered nurse and is proud to have supported the Orange County community during the height of the COVID pandemic. Guthrie treats patients of all ages and walks of life, with a particular interest in Transcranial Magnetic Stimulation (TMS) Therapy, the specialty of TMSHW.

Key Points: 
  • Guthrie treats patients of all ages and walks of life, with a particular interest in Transcranial Magnetic Stimulation (TMS) Therapy, the specialty of TMSHW.
  • "TMS Health and Wellness is delighted to welcome Sylvia to our patient care team," says Dr. Claudia Eppele, M.D., founder and Chief Medical Officer at TMS Health and Wellness.
  • TMS Health and Wellness continues to advance treatment alternatives by offering both rTMS and Deep Transcranial Magnetic Stimulation (dTMS), utilizing the latest H-coil technology.
  • About TMS Health and Wellness: Founded by Harvard-trained doctor, Claudia Eppele M.D., TMS Health and Wellness is one of the nation's premier Transcranial Magnetic Stimulation therapy centers.